Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gandouling vs Zinc Gluconate for Wilson's Disease
NCT05305872Phase 4
Key facts
- Status
- Recruiting
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Countries
- 1
- Modality
- HM (Herbal Medicine)
- Drugs
- gandouling
- Conditions
- Wilson's disease
01
Overview
Phase 4, randomised, double-blind trial of gandouling in Wilson's disease (2 arms). Primary endpoint: Unified Wilson's Disease Rating Scale at 24 weeks. Started Jan 2023; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Treatment group
Gandouling + Zinc gluconate simulant
Control group
Zinc gluconate + Gandouling simulant
03
Who it enrols
Patients aged 15 or older with Wilson's disease (phlegm and blood stasis syndrome) are eligible. Patients with severe cerebral or liver WD, severe psychiatric symptoms, or recent seizures are excluded.
04
Endpoints
Primary
Unified Wilson's Disease Rating Scale
Secondary
24-hour urinary copper
non-ceruloplasmin bound copper
Beyond the preview
Go deeper on NCT05305872.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305872.